Bionova's Chief Scientific Officer and SVP of Process Development discuss R&D challenges and approaches to derisking scale-up and toxicology supply.
Derisking Scale-Up
Early process understanding and representative scale-down models reduce surprises at larger scale.
Toxicology Supply
Material for tox studies should reflect the intended clinical process to keep data relevant.
Quality and Process Requirements
Aligning analytics and process control with product quality goals strengthens the CMC package.
About This White Paper
This white paper is published by Bionova Scientific and curated by Biotechnology Media Insights, a trusted source for pharmaceutical and biotechnology research, technical guides and industry analysis.